Insider Selling: Outset Medical, Inc. (NASDAQ:OM) CTO Sells 8,306 Shares of Stock

Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CTO Jean-Olivier Racine sold 8,306 shares of the firm's stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $3.27, for a total value of $27,160.62. Following the transaction, the chief technology officer now owns 265,325 shares of the company's stock, valued at $867,612.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jean-Olivier Racine also recently made the following trade(s):

• On Thursday, February 15th, Jean-Olivier Racine sold 1,866 shares of Outset Medical stock. The stock was sold at an average price of $3.57, for a total transaction of $6,661.62.

Outset Medical Stock Down 6.1 %

Shares of NASDAQ OM traded down $0.20 during midday trading on Friday, hitting $3.07. 1,434,772 shares of the stock traded hands, compared to its average volume of 1,228,462. The company has a debt-to-equity ratio of 1.06, a quick ratio of 4.37 and a current ratio of 5.26. Outset Medical, Inc. has a one year low of $1.92 and a one year high of $24.13. The business has a 50 day moving average price of $2.50 and a two-hundred day moving average price of $3.75. The company has a market cap of $158.73 million, a PE ratio of -0.91 and a beta of 1.85.

Outset Medical (NASDAQ:OM - Get Free Report) last posted its earnings results on Wednesday, February 21st. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.03). Outset Medical had a negative net margin of 132.54% and a negative return on equity of 102.50%. The company had revenue of $30.51 million during the quarter, compared to the consensus estimate of $30.40 million. On average, equities analysts predict that Outset Medical, Inc. will post -2.28 EPS for the current year.

Analyst Ratings Changes

OM has been the subject of a number of analyst reports. CL King raised shares of Outset Medical from a "neutral" rating to a "buy" rating and set a $6.00 target price for the company in a research note on Friday, April 5th. BTIG Research initiated coverage on Outset Medical in a research report on Monday, April 8th. They set a "buy" rating and a $6.00 target price on the stock. Finally, Royal Bank of Canada downgraded shares of Outset Medical from an "outperform" rating to a "sector perform" rating and reduced their price objective for the stock from $14.00 to $6.00 in a research report on Friday, January 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $5.42.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of OM. State Board of Administration of Florida Retirement System grew its stake in Outset Medical by 33.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 18,842 shares of the company's stock valued at $42,000 after acquiring an additional 4,720 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Outset Medical by 1,317.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 8,790 shares of the company's stock valued at $48,000 after purchasing an additional 8,170 shares in the last quarter. RPO LLC bought a new position in shares of Outset Medical in the fourth quarter worth $76,000. Valeo Financial Advisors LLC purchased a new stake in shares of Outset Medical in the fourth quarter worth $117,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Outset Medical in the fourth quarter worth $161,000.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.